BioBusiness

A review of the past year's trends in biopharmaceutical approvals shows an above average approval rate.

China's regulatory and compliance environment is set to change as the government declares a crackdown on bribery scandals.

Conference programming from PDA and BioPharm International expand educational opportunities at Interphex 2014.

Moody's Investor Service reports AbbVie, Amgen, and Roche are the most exposed to biosimilar competition.

Thirteen companies are accepted for participation in the supply chain program.

The biopharmaceutical industry contemplates product innovation within the changing landscape of healthcare.

With numerous biologics set to come off patent soon and the percentage of new therapeutics based on biomolecules growing, demand for contract manufacturing in the biopharma space is heating up.

In 2013, the EMA's Committee for Medicinal Products for Human Use recommended 81 medicines for human use for marketing authorization, compared with 57 in 2012.

Generics, market dynamics, and global demand are changing drug spending patterns.

Frenzy cools as investors seeking a quick return turn elsewhere.

Brazil is the first Latin American country to emerge as a global biopharmaceutical collaborator.

Almost 400 new medicines for infectious diseases, including viral infections, bacterial infections, fungal infections and parasitic infections.

The little-known exception to the patent term extension law is potentially valuable but easy to miss.

The biopharmaceutical industry must consider new ways to manage innovation, including how product data are handled.

Caution should be taken when planning to crowdfund a biopharmaceutical startup.

Higher wages and employment rates give biopharm professionals an edge over counterparts in other industries.

Israel's diverse population, high-quality healthcare system, and resilience to global financial stress make it a strong partner for R'D, clinical research, and market growth.

The employment picture brightened a bit, but biopharma employees still seek better compensation.

The rising cost of drug development and the decreasing proportion of drug-naive population in the US and European markets are driving international pharmaceutical companies to consider emerging markets as a location to conduct their clinical trials. Asia stands out among the emerging markets given its double-digit growth rates.

New regulation offers patients in Brazil greater access to experimental drugs.

Today, there is a global adoption of buying and selling used equipment. This article reviews what organizations should look for when considering the purchase of used equipment.

The pharmaceutical industry grows despite conflict in the Middle East.

The authors review the angiopoietin pathway as an alternative for safer and more efficacious anti-angiogenic therapeutics.

Foreign companies zero in on Myanmar with the hope of securing a foothold in its pharmaceutical market.

Early-stage companies are now embraced by buyers of new issues.

Pharma eyes biologics production in Brazil as the government begins to recognize the potential of these drugs.

PDA/FDA regulatory conference promotes a commitment to quality.

The bio-pharmaceutical business outlook in South Korea remains positive

The US Supreme Court's Myriad decision satisfied both patient groups and patent holders

Pharmaceutical companies have stepped up gene therapy development in the wake of the approval of Glybera in 2012.